Literature DB >> 9028330

Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin.

L Krenacs1, A Wellmann, L Sorbara, A W Himmelmann, E Bagdi, E S Jaffe, M Raffeld.   

Abstract

Anaplastic large cell lymphoma (ALCL) is composed of large, frequently bizarre, cells of T- or null-cell phenotype that show a preferential sinusoidal growth pattern and consistent CD30 positivity. Whether these tumors represent a single entity or several, and what the exact cell origin, is controversial. Recently, granzyme B, a cytotoxic granule component, was reported in a small percentage of ALCL, suggesting that some cases may originate from cytotoxic lymphocytes. To further investigate this possibility, we performed an immunohistochemical study of 33 ALCLs of T- and null-cell type, using monoclonal antibodies to cytotoxic cell-associated antigens, including CD8, CD56, CD57, and the cytotoxic granular proteins perforin and TIA-1. In addition, CD4 expression was also evaluated. ALCL cases included 27 classical systemic forms and variants, 3 primary cutaneous (PC) forms, and 3 acquired immunodeficiency syndrome-associated forms. Cytotoxic antigen expression was also studied in 51 cases of Hodgkin's disease (HD) and 17 large B-cell lymphomas (LBCLs) with anaplastic cytomorphology and/ or CD30 positivity. We found that 76% of ALCLs, representing all subtypes except the PC forms, expressed either TIA-1, perforin, or both proteins. Expression of TIA-1 and perforin were highly correlated (P < .001). On the basis of their immunophenotypic profiles, several subtypes of cytotoxic antigen positive and negative ALCL could be recognized. Fifty-five percent of ALCLs (18 of 33) displayed an immunophenotypic profile consistent with cytotoxic T cells. Six cases expressed cytotoxic granular proteins in the absence of lineage specific markers, and one case expressed both T-cell- and natural killer cell-like markers. These 7 cases (21%) were placed into a phenotypic category of cytotoxic lymphocytes of unspecified subtype. Twenty-four percent (8 cases) of ALCLs were cytotoxic granule protein negative. All but one of these displayed a T-cell phenotype. Cytotoxic granule protein expression did not correlate with the presence of the NPM-ALK fusion transcript. Only 10% of the 51 HD cases were found to be TIA-1+, and none expressed perforin. Cytotoxic antigen expression was absent in LBCL. The expression of cytotoxic granule proteins in the majority of ALCL implies a cytotoxic lymphocyte phenotype and suggests that most cases originate from lymphocytes with cytotoxic potential. Furthermore, the demonstration of cytotoxic cell related proteins may be a useful addition to the current panel of antibodies used to distinguish ALCL, HD, and anaplastic LBCL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028330

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.

Authors:  E Berti; D Tomasini; M H Vermeer; C J Meijer; E Alessi; R Willemze
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  TiA1 in advanced-stage classical Hodgkin's lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells.

Authors:  Sophie Camilleri-Broët; Christophe Fermé; Françoise Berger; Eric Lepage; Serge Bain; Josette Brière; Béatrice Marmey; Philippe Gaulard; Josée Audouin
Journal:  Virchows Arch       Date:  2004-06-19       Impact factor: 4.064

Review 3.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

4.  TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation.

Authors:  R E Felgar; W R Macon; M C Kinney; S Roberts; T Pasha; K E Salhany
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

5.  A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.

Authors:  D F Dukers; R L ten Berge; J J Oudejans; K Pulford; D Hayes; J F Miseré; G J Ossenkoppele; L H Jaspars; R Willemze; C J Meijer
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

6.  CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation.

Authors:  Soumya Sundara Rajan; Lingxiao Li; Mercedes F Kweh; Kranthi Kunkalla; Amit Dipak Amin; Nitin K Agarwal; Francisco Vega; Jonathan H Schatz
Journal:  Blood Adv       Date:  2019-06-25

7.  Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype.

Authors:  D F Dukers; M H Vermeer; L H Jaspars; C A Sander; M J Flaig; W Vos; R Willemze; C J Meijer
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

8.  Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type.

Authors:  Naoko Asano; Tomohiro Kinoshita; Jun-Ichi Tamaru; Koichi Ohshima; Tadashi Yoshino; Nozomi Niitsu; Norifumi Tsukamoto; Kaoru Hirabayashi; Koji Izutsu; Masafumi Taniwaki; Yasuo Morishima; Shigeo Nakamura
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

9.  Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.

Authors:  M H Vermeer; F A Geelen; J A Kummer; C J Meijer; R Willemze
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

10.  Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas.

Authors:  M L Boulland; V Meignin; K Leroy-Viard; C Copie-Bergman; J Brière; R Touitou; P Kanavaros; P Gaulard
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.